Company / Return on Equity (ROE)
BeOne Medicines Ltd. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
6.6%
FY2025
5-year range
-45.7% / 6.6%
FY2021-FY2025
Trend
+134.0%
vs FY2024
Sector context
#41 of 190
Health Care
What the data says
BeOne Medicines Ltd.'s return on equity (roe) of 6.6% is higher than 78% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has increased for 3 consecutive years, from -45.7% in FY2022 to 6.6% in FY2025.
Based on SEC 10-K filings.
6.6% in FY2025 with a 5-year CAGR of +48.6%. Top quartile in the Health Care sector.
Improved from -24.9% to 6.6% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +52.3pp
- 5-Year Change
- +48.6pp
- 10-Year Change
- -
Sector benchmark
+113.0% above sector average
Key checks
Key Insights
- BeOne Medicines Ltd.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 134.0% year-over-year.
- Currently 57.0pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 6.6% | +134.0% |
| FY2024 | -19.4% | +22.4% |
| FY2023 | -24.9% | +45.5% |
| FY2022 | -45.7% | -92.3% |
| FY2021 | -23.8% | +43.4% |
| FY2020 | -42.0% | +57.4% |
| FY2019 | -98.6% | -154.5% |
| FY2018 | -38.7% | -178.7% |
| FY2017 | -13.9% | +58.9% |
| FY2016 | -33.8% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026